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BACKGROUND: Short-course radiation followed by
chemotherapy as total neoadjuvant therapy has been
investigated primarily in Europe and Australia with
increasing global acceptance. There are limited data
on this regimen’s use in the United States, however,
potentially delaying implementation.

SETTING: This study was performed at a National Cancer
Institute-designated cancer center.

OBJECTIVE: This study aimed to compare clinical
performance and oncologic outcomes of 2 rectal cancer
neoadjuvant treatment modalities: short-course total
neoadjuvant therapy versus standard chemoradiation.

INTERVENTIONS: There were 187 patients treated
with short-course total neoadjuvant therapy (5 × 5 Gy
radiation followed by consolidation oxaliplatin-based
chemotherapy) compared with 226 chemoradiation
recipients (approximately 50.4 Gy radiation in 28
fractions with concurrent fluorouracil equivalent).

DESIGN: This is a retrospective cohort study.
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PATIENTS: A total of 413 patients had locally advanced
rectal cancers diagnosed from June 2009 to May 2018 and
received either short-course total neoadjuvant therapy or
standard chemoradiation.

MAIN OUTCOME MEASURES: Primary end points were
tumor downstaging, measured by complete response and
“low” neoadjuvant rectal score rates, and progressionfree survival. Secondary analyses included treatment
characteristics and completion, sphincter preservation,
and recurrence rates.
RESULTS: Short-course total neoadjuvant therapy
was associated with higher rates of complete response
(26.2% vs 17.3%; p = 0.03) and “low” neoadjuvant
rectal scores (40.1% vs 25.7%; p < 0.01) despite
a higher burden of node-positive disease (78.6%
vs 68.9%; p = 0.03). Short-course recipients also
completed trimodal treatment more frequently
(88.4% vs 50.4%; p < 0.01) and had fewer months with
temporary stomas (4.8 vs 7.0; p < 0.01). Both regimens
achieved comparable local control (local recurrence:
2.7% short-course total neoadjuvant therapy vs 2.2%
chemoradiation, p = 0.76) and 2-year progression-free
survival (88.2% short-course total neoadjuvant therapy
(95% CI, 82.9–93.5) vs 85.6% chemoradiation (95% CI,
80.5–90.7)).
DISEASES OF THE COLON & RECTUM VOLUME 65: 2 (2022)
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LIMITATIONS: Retrospective design, unbalanced
disease severity, and variable dosing of neoadjuvant
consolidation chemotherapy were limitations of this
study.
CONCLUSIONS: Short-course total neoadjuvant
therapy was associated with improved downstaging
and similar progression-free survival compared with
chemoradiation. These results were achieved with
shortened radiation courses, improved treatment
completion, and less time with diverting ostomies.
Short-course total neoadjuvant therapy is an optimal
regimen for locally advanced rectal cancer. See Video
Abstract at http://links.lww.com/DCR/B724.

TERAPIA NEOADYUVANTE TOTAL CON RADIACIÓN DE
CORTA DURACIÓN: EXPERIENCIA ESTADOUNIDENSE
DE UNA TERAPIA NEOADYUVANTE CONTRA EL CÁNCER
DE RECTO
ANTECEDENTES: La radiación de corta duración seguida
de quimioterapia como terapia neoadyuvante total se ha
investigado principalmente en Europa y Australia con
una aceptación mundial cada vez mayor. Sin embargo,
datos limitados sobre el uso de este régimen en los
Estados Unidos, han potencialmente retrasando su
implementación.
OBJETIVO: Comparar el desempeño clínico y los
resultados oncológicos de dos modalidades de
tratamiento neoadyuvante del cáncer de recto:
terapia neoadyuvante total de corta duración versus
quimioradiación. estándar.
DISEÑO: Cohorte retrospectivo.
AJUSTE: Centro oncológico designado por el NCI.
PACIENTES: Un total de 413 cánceres rectales localmente

avanzados diagnosticados entre junio de 2009 y mayo
de 2018 que recibieron cualquiera de los regímenes
neoadyuvantes.

INTERVENCIONES: Hubo 187 pacientes tratados con
terapia neoadyuvante total de ciclo corto (radiación
5 × 5 Gy seguida de quimioterapia de consolidación
basada en oxaliplatino) en comparación con 226
pacientes de quimiorradiación (aproximadamente 50,4
Gy de radiación en 28 fracciones con equivalente de
fluorouracilo concurrente).
PRINCIPALES MEDIDAS DE RESULTADO: Los criterios
primarios de valoración fueron la disminución del
estadio del tumor, medido por la respuesta completa
y las tasas de puntuación rectal neoadyuvante “baja”,
y la supervivencia libre de progresión. Los análisis
secundarios incluyeron las características del tratamiento
y las tasas de finalización, conservación del esfínter y
recurrencia.

RESULTADOS: La terapia neoadyuvante total de corta
duración, se asoció con tasas más altas de respuesta
completa (26,2% versus 17,3%, p = 0,03) y puntuaciones
rectales neoadyuvantes “bajas” (40,1% versus 25,7%,
p < 0,01) a pesar de una mayor carga de enfermedad
con ganglios positivos (78,6% versus 68,9%, p = 0,03).
Los pacientes de ciclo corto también completaron el
tratamiento trimodal con mayor frecuencia (88,4% versus
50,4%, p < 0,01) y tuvieron menos meses con estomas
temporales (4,8 versus 7,0, p < 0,01). Ambos regímenes
lograron un control local comparable (recidiva local: 2,7%
de SC-TNT versus 2,2% de TRC, p = 0,76) y supervivencia
libre de progresión a 2 años (88,2% de SC-TNT [IC: 82,9 93,5] versus 85,6% CRT [CI: 80,5 - 90,7]).
LIMITACIONES: Diseño retrospectivo, gravedad de la
enfermedad desequilibrada y dosificación variable de
quimioterapia neoadyuvante de consolidación.
CONCLUSIONES: La terapia neoadyuvante total de
ciclo corto se asoció con una mejora en la reducción
del estadio y una supervivencia libre de progresión
similar en comparación con la quimioradiación. Estos
resultados se lograron con ciclos de radiación más cortos,
tratamientos mejor finalizados y menos tiempo en
ostomías de derivación. La terapia neoadyuvante total de
corta duración es un régimen óptimo para el cáncer de
recto localmente avanzado. Consulte Video Resumen en
http://links.lww.com/DCR/B724. (Traducción- Dr. Fidel
Ruiz Healy)
KEY WORDS: Neoadjuvant therapy; Rectal cancer; Shortcourse radiation; Total neoadjuvant therapy.

L

ocally advanced rectal cancer has traditionally been
treated with neoadjuvant chemoradiation therapy (CRT), surgery, and adjuvant chemotherapy in
the United States. Within the past decade, however, multiple
reports have described a promising new strategy, termed total
neoadjuvant therapy (TNT). Early regimens, predominately
composed of induction chemotherapy followed by CRT,
have achieved higher trimodal therapy completion rates and
better tumor downstaging than traditional therapy.1,2
However, TNT regimens that include consolidation instead of induction chemotherapy3 or replace CRT
with short-course (5 × 5 Gy) radiation4,5 have also shown
early promise and offer unique advantages. In particular,
short-course radiation reduces overall treatment duration,
patient burden, and costs by cutting radiation fractions
from 28 to 5.6 In this environment, European consensus
guidelines now recommend a TNT approach incorporating short-course radiotherapy.7 Despite these potential
advantages, the implementation of short-course radiation
and TNT in North America has been rare.8
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Since 2016, short-course radiation with TNT
(SC-TNT) has been the standard neoadjuvant regimen for
locally advanced rectal cancer at Washington University.
Based on anecdotal clinical experience and limited phase
II data,5 we hypothesized that SC-TNT would be associated with increased tumor downstaging, longer progression-free survival, and fewer fractions of radiation.
Herein, we report the clinical performance metrics and
early oncologic outcomes of an SC-TNT regimen utilized
at our center during the past decade.

METHODS
Study Population

Patients with locally advanced rectal cancer who underwent neoadjuvant CRT or SC-TNT at our National Cancer
Institute-designated cancer center from June 2009 to May
2018 were selected for inclusion in this retrospective
cohort study. We defined locally advanced rectal cancer
as biopsy-proven adenocarcinoma located within 15 cm of
the anal verge on digital or rigid proctoscopic examination
with clinical staging of T3/T4 N0 or T(any) N+.9 Local
staging was accomplished by endorectal ultrasound or
MRI, whereas CT of the chest, abdomen, and pelvis evaluated patients for distant disease. Although the modality of
local staging varied before 2014, lymph nodes, in general,
were evaluated in terms of overall size, border irregularity,
signal intensity heterogeneity, and shape.10 Patients were
excluded if they had recurrent or metastatic disease at presentation, had previous rectal surgery or local resection,
did not undergo neoadjuvant treatment, or were medically unfit for resection at the time of diagnosis. This study
was approved by the Washington University Institutional
Review Board.
Treatment Regimens

Cohorts were assembled on the basis of the neoadjuvant
treatment regimen received (Fig. 1). Chemoradiation
involved 45 to 55 Gy of pelvic radiation delivered over

25 to 28 consecutive fractions with a concurrent fluorouracil-equivalent radiosensitizer. Radiation was delivered
with 3-dimensional conformal radiotherapy or intensitymodulated radiotherapy. Standard dosing of 50.4 Gy
was delivered in most cases, although select boosting of
extramesorectal nodes or bulky tumors resulted in cumulative doses up to 55 Gy. After an approximate 1-month
recovery period, patients underwent standard total mesorectal excision (TME).11 Adjuvant chemotherapy with a
fluoropyrimidine and oxaliplatin was administered at the
discretion of the treating medical oncologist.
The SC-TNT regimen was composed of hypofractionated pelvic radiation followed by consolidation chemotherapy. Radiation was delivered in 5 consecutive
fractions of 5 Gy for a total dose of 25 Gy.5 In cases of
lymphadenopathy beyond the predicted resection margin,
the dose was boosted to 7 Gy per fraction (total dose of 35
Gy). After 2 to 4 weeks of postradiation recovery, patients
received between 2 and 6 months of platinum-based consolidation chemotherapy, most commonly mFOLFOX6.
The duration of neoadjuvant chemotherapy varied over
the study period because of several factors. Initial testing
of the SC-TNT regimen for safety was performed with
2 months of preoperative chemotherapy and was largely
applied to patients with bulky nodal disease. After 2012,
more chemotherapy was added to the neoadjuvant course,
eventually evolving into the current standard of 8 cycles.
Chemotherapy dosing also varied by individual patient
factors and treating oncologist practice patterns. Adjuvant
chemotherapy administration was left to the discretion of
the treating medical oncologist and varied by neoadjuvant
dosing, tumor characteristics on pathologic evaluation,
and oncologist treatment practices.
In the SC-TNT cohort, definitive nonoperative management was utilized selectively. Patients without evidence
of residual disease on clinical, endoscopic, and radiographic restaging after completion of SC-TNT were eligible
for “watch and wait.”12 Surveillance, consisting of quarterly
clinical examinations, endoscopy, and pelvic MRIs, was

Standard chemoradiation therapy (CRT)
Dx

CRT

Recovery

Surgery

Chemotherapy

Recovery

Ostomy
reversal
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scRT

Short-course radiation with total neoadjuvant therapy (SC-TNT)
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1
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3
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FIGURE 1. Timelines demonstrating standard treatment course for patients undergoing neoadjuvant treatment for locally advanced rectal
cancer with either chemoradiation therapy or short-course radiation with total neoadjuvant therapy. Dx = diagnosis; scRT = short-course
radiation therapy.
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used to monitor clinical responders for regrowth for the
first 2 years after treatment conclusion. Thereafter, examination frequencies were gradually reduced.13
Neoadjuvant regimen selection depended on the location of therapy administration. Patients receiving treatment at outside facilities throughout the study period
almost exclusively received CRT. At our institution before
2016, short-course radiation was the modality of choice
except in select ultra-low tumors, which intermittently
received CRT at the discretion of the treating radiation
oncologist. During the same time period, neoadjuvant
consolidation chemotherapy was predominantly administered to tumors with concerning features such as positive circumferential resection margin or significant nodal
disease, whereas patients with favorable clinical staging
typically received only radiation followed by immediate
surgery. Beginning in 2016, however, SC-TNT became the
institutional standard therapy for all locally advanced rectal cancers treated within our institution.
Outcomes

The primary outcomes are tumor downstaging and progression-free survival. Downstaging was assessed by the
rate of complete response (CR) and the rate of achieving a Neoadjuvant Rectal (NAR) score below 8 (“low”).14
When resected, patients were considered to achieve CR if
the pathologic specimen was devoid of viable tumor cells
(pathologic complete response). For those nonoperatively
managed, absence of tumor regrowth or distant recurrence after 12 months of active surveillance was considered a CR.1 The NAR score is a composite short-term end
point designed to measure tumor response to neoadjuvant rectal cancer therapy; a “low” score (<8) has been
associated with significantly improved survival in large
rectal cancer trials.14 The NAR score was calculated using
clinical T, pathologic T, and pathologic N stages for each
cancer (Supplementary Equation 1 at http://links.lww.
com/DCR/B726); patients who did not undergo TME
and experienced a durable CR were assumed to have pT
= 0, pN = 0 for NAR calculation purposes.14 Progressionfree survival was defined as the time from cancer diagnosis to metastasis, local recurrence, distant recurrence,
or death from any cause; patients who experienced none
of these events were censored at the last recorded followup visit. Progression-free survival was chosen as the primary long-term oncologic outcome end point because
duration, order, and modalities of therapy varied highly
between cohorts.
Secondary outcomes included recurrence rates, treatment-specific characteristics including time to treatment
initiation and surgery, sphincter-preservation rates, trimodal therapy completion rate, and cumulative time with
a temporary ostomy. Analysis of trimodal treatment completion, defined as completion of intended radiotherapy,

3 months of oxaliplatin-containing chemotherapy, or any
chemotherapy in the setting of a CR, and surgery (except
in the setting of nonoperative management), was limited
to patients with nonmissing chemotherapy data.
Statistical Analysis

Differences in cohort demographics, downstaging, recurrence, treatment characteristics, and sphincter preservation were analyzed with univariate χ2 or Kruskal-Wallis
tests. Disease-free survival analysis was performed by the
Kaplan-Meier product-limit method with a log-rank test
for statistical difference. Multivariable logistic regression
analysis of CR was performed to identify adjusted associations between clinical variables and the primary end point.
A level of significance where p < 0.05 was chosen a priori
for all hypothesis testing. All analyses were performed
with SAS version 9.4 (SAS Institute, Cary, NC).

RESULTS
A total of 413 eligible patients were treated with CRT
(226) or SC-TNT (187) before TME or definitive nonoperative management (Table 1). Although both cohorts
included similar age, sex, and clinical T-stage characteristics, SC-TNT recipients were more likely to have
advanced nodal disease (cN2) (39.0% vs 16.8%; p < 0.01)
but less likely to have distal tumors (34.2% vs 47.3%;
p < 0.01). Treatment selection was also unevenly distributed over time; whereas both regimens were used evenly
from 2009 to 2012, CRT was clearly favored in the middle
3 years before the institutional shift to SC-TNT in 2016.
Accordingly, follow-up time among both cohorts was
widely distributed with interquartile ranges varying from
1.5 to 5 years (p = 0.12).
Tumor Downstaging and Sphincter Preservation

Short-course total neoadjuvant therapy was significantly
associated with higher tumor downstaging. Complete
response rates were over 50% higher in the SC-TNT cohort
than in the CRT group (26.2% vs 17.3%; p = 0.03; Table 2).
Similarly, “low” NAR scores were significantly more common among SC-TNT recipients (40.1% vs 25.7%; p <
0.01). Short-course total neoadjuvant therapy (OR, 2.23;
p < 0.01) remained significantly associated with CR after
adjusting for cohort-level differences in multiple clinical
variables (Supplementary Table 1 at http://links.lww.com/
DCR/B727). Other significant associations included age
over 75 years (OR, 3.07; p = 0.02) and T2 clinical stage
(OR, 5.12; p < 0.01). Of note, the duration of time between
radiation completion and surgery and the dose of neoadjuvant chemotherapy were not independently associated
with CR on univariate analysis and were not included in
the multivariable regression because of significant collinearity with the neoadjuvant treatment regimen.
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TABLE 1. Study population demographic characteristics (%)
Neoadjuvant regimen
Variable
Age, y, n (%)
<50
50–75
>75
Sex, n (%)
Male
Female
Year of enrollment, n (%)
2009–2012
2013–2015
2016–2018
Clinical T stage, n (%)
T1
T2
T3
T4
Missing
Clinical N stage, n (%)
N0
N1
N2
Missing
Clinical CRM status, n (%)
Negative
Close (within 2 mm)
Positive
Missing
Modality for clinical staging, n (%)
ERUS
MRI
MRI and ERUS
Biopsy
Missing
Tumor height
Median, cm (IQR)
Low (<5 cm), n (%)
Mid (5–10 cm), n (%)
High (>10 cm), n (%)
Missing, n (%)
Oncologic follow-up, mo
Median (IQR)

CRT
(n = 226)

SC-TNT
(n = 187)

44 (19.4)
160 (70.8)
22 (9.7)

44 (23.5)
124 (66.3)
19 (10.2)

0.48

151 (66.8)
75 (33.2)

115 (61.5)
72 (38.5)

0.26

72 (31.9)
118 (52.2)
36 (15.9)

69 (36.8)
14 (7.5)
104 (55.6)

<0.01

1 (0.4)
16 (7.1)
175 (77.4)
29 (12.9)
5 (2.2)

1 (0.5)
15 (8.0)
142 (75.9)
26 (13.9)
3 (1.6)

0.76

70 (31.0)
117 (51.8)
38 (16.8)
1 (0.4)

40 (21.4)
74 (39.6)
73 (39.0)
0 (0.0)

<0.01

75 (33.2)
6 (2.7)
41 (18.1)
104 (46.0)

76 (40.6)
18 (9.6)
44 (24.1)
49 (26.2)

<0.01

85 (37.6)
126 (55.8)
1 (0.4)
3 (1.3)
11 (4.9)

41 (21.9)
136 (72.7)
4 (2.1)
0 (0.0)
6 (3.2)

<0.01

5 (3–8)
107 (47.3)
75 (33.2)
27 (12.0)
17 (7.5)

7 (4–10)
0.04
64 (34.2) <0.01
103 (55.1)
14 (7.5)
6 (3.2)

41.6
(19.2–62.6)

28.3
(18.9–61.4)

p value

Progression-Free Survival and Recurrence

Overall and site-specific recurrence patterns did not significantly vary between cohorts (Table 2); 15.6% of patients
receiving SC-TNT experienced a recurrence compared
with 17.4% of CRT recipients over the follow-up period
(p = 0.64). Both neoadjuvant regimens achieved pelvic
recurrence rates less than 5%, but distant recurrences were
higher in both cohorts (10.7% SC-TNT vs 13.3% CRT;
p = 0.42). Specific 2-year disease-free survival was also
similar (88.2% SC-TNT (95% CI, 82.9–93.5) vs 85.6%
CRT (95% CI, 80.5–90.7)), and there was no significant
difference between cohorts on Kaplan-Meier analysis (log
rank p = 0.95; Fig. 2).
Treatment Delivery Characteristics

Treatment delivery varied significantly (Table 3). Shortcourse total neoadjuvant therapy was associated with
higher trimodality treatment completion rates (88.4%
vs 50.4%; p < 0.01) and shorter intervals from diagnosis to consolidative chemotherapy initiation (median, 1.9
months (interquartile range (IQR), 1.6–2.5) vs 6.4 months
(IQR, 5.8–7.2); p < 0.01) compared with CRT. Although
the median time to starting any therapy was similar
(1.1 months (IQR, 0.8–1.6) for both SC-TNT and CRT;
p = 0.59), SC-TNT was associated with a longer interval
from diagnosis to surgery (median, 6.2 months (IQR, 5.1–
7.7) vs 4.7 months (IQR, 4.1–5.2); p < 0.01). Overall, total
treatment time from diagnosis to diverting stoma reversal
was shorter in the SC-TNT cohort (median, 10.8 months
(IQR, 10.0–12.3) vs 11.5 months (IQR, 10.2–13.6); p = 0.02).

DISCUSSION

0.12

CRM = circumferential resection margin; CRT = chemoradiation therapy; ERUS =
endorectal ultrasound; IQR = interquartile range for variables described by median
values; SC-TNT = short-course radiation with total neoadjuvant therapy.

In the overall study population, there was a positive
association between SC-TNT and sphincter preservation (73.0% vs 60.6%; p < 0.01; Table 2). For patients
with tumors smaller than 5 cm, the sphincter-preservation rates were similar between treatment groups (33.3%
SC-TNT vs 31.8% CRT; p = 0.83). However, among
patients who underwent sphincter-preserving resection
with temporary diversion, SC-TNT was associated with
significantly shorter duration of diversion (4.8 vs 7.0
months; p < 0.01).

In North America, neoadjuvant short-course pelvic radiation is infrequently prescribed for locally advanced rectal
cancer.15,16 Despite data from Australasia17 and Europe,4,18
critics argue that condensed dosing risks toxicity, longterm bowel complications, and poorer oncologic outcomes
compared with CRT.8,19,20 When incorporated into a “total
neoadjuvant” approach, however, we found that shortcourse radiation was associated with excellent oncologic
outcomes, improved rates of trimodal therapy completion,
and reduced burden of stoma frequency and duration.
Most importantly, SC-TNT was associated with significantly more tumor downstaging, particularly complete responses, than CRT. More than 26% of tumors in
the SC-TNT group achieved a CR compared with 17% of
CRT recipients, and the odds of CR (OR 2.23) were more
than 100% higher for patients undergoing SC-TNT. Shortcourse total neoadjuvant therapy was also associated with a
significantly higher proportion of “favorable” NAR scores
than CRT. Notably, these results were achieved without
increased risk of perioperative complications as reported
previously.21
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TABLE 2. Outcomes (%)
Neoadjuvant regimen
Outcome

CRT

Sphincter preservation, n (%)
Overall
137 (60.6)
Low tumors
34 (31.8)
Months with temporary stoma
Median (IQR)
7.0 (5.8–8.7)
Downstaging, n (%)
CR
39 (17.3)
Low NAR score
58 (25.7)
Recurrence, n (%)
Total
38 (17.4)
  Local
5 (2.2)
  Distant
30 (13.3)
  Both
3 (1.3)

SC–TNT
135 (73.0)
21 (33.3)

p value
<0.01
0.83

4.8 (3.5–6.2)

<0.01

49 (26.2)
75 (40.1)

0.03
<0.01

28 (15.6)
5 (2.7)
20 (10.7)
3 (1.6)

0.64
0.76
0.42
0.81

Analysis limited to patients for whom all chemotherapy details, including dates of
treatment, were known.
CR = complete response; CRT = chemoradiation therapy; IQR = interquartile range
for variables described by median values; NAR = Neoadjuvant Rectal Score; SC-TNT
= short-course radiation with total neoadjuvant therapy.

Similar associations between tumor downstaging and
“total neoadjuvant” regimens utilizing chemoradiation have
been previously reported. Cercek et al1 found that higher rates
of both pathologic complete response (pCR) and successful nonoperative management were significantly associated
with induction chemotherapy followed by chemoradiation
compared with chemoradiation alone. In the Chinese randomized “FOWARC” trial, the chemoradiation-based TNT
arm achieved significantly higher complete response rates
(27.5%) vs standard treatment (14.0%).22 Additionally, the
multiarmed phase II TIMING study of chemoradiation
plus varying amounts of consolidative chemotherapy found

stepwise increases in CR rates from 25% to 38% with the
addition of more chemotherapy cycles.3
Previous assessments of the downstaging potential of
TNT regimens incorporating short-course radiotherapy,
however, offer mixed conclusions. In 2016, the Polish
Colorectal Study Group reported no difference in pCR
among patients with large, advanced tumors (fixed cT3 or
cT4) treated with either chemoradiation and concurrent
oxaliplatin infusions (12%) or a TNT regimen of 5 × 5 Gy
radiation followed by 3 cycles of consolidation FOLFOX
(16%; p = 0.17).4 There was also no reported difference
in disease-free survival. However, the recently released
RAPIDO trial reported drastically different findings: 5
× 5 Gy radiation followed by approximately 4 months of
consolidation chemotherapy achieved significantly more
pCRs (27.7%) compared with chemoradiation (13.8%; p <
0.01) in a population of similarly advanced cancers (cT4,
cN2, or involved mesorectal fascia).23 And, the SC-TNT
arm experienced significantly fewer disease-related treatment failures compared with chemoradiation recipients
(23.7% vs 30.4%; p = 0.02). The divergent results of these
2 large, randomized European studies may be related to
the significantly higher cumulative dose of consolidation
chemotherapy or longer time interval between radiation
completion and resection in the RAPIDO trial. This is also
consistent with the TIMING study conclusions, which
showed that more chemotherapy after chemoradiation was
associated with a higher yield of pCR. The SC-TNT regimen examined in this article mirrors the RAPIDO experimental protocol much more closely, perhaps explaining
the similar pCR rates (26.2% vs 27.7%) between that randomized trial and the observational data reported herein.
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FIGURE 2. Progression-free survival curves for patients undergoing neoadjuvant treatment with either CRT (solid blue line) or SC-TNT
(dashed red line). CRT = chemoradiation therapy; SC-TNT = short course radiation with total neoadjuvant therapy.
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TABLE 3. Treatment characteristics by cohort (%)
Treatment variable
Radiation
Total radiation dose received, Gy, median (IQR)
Chemosensitizer use, n (%)
  Yes
  No
Months from diagnosis to initiation, median (IQR)
Chemotherapya
Months from diagnosis to initiation, median (IQR)
Neoadjuvant consolidation chemotherapy cycles
  Median (IQR)
   None, n (%)
   1–5, n (%)
   6–12, n (%)
Adjuvant consolidation chemotherapy, n (%)
  Yes
  No
  Missing
Total consolidation chemotherapy cycles
  Median (IQR)
   <6, n (%)
   ≥6, n (%)
Chemotherapy dose reduction, n (%)
  Yes
  No
Surgeryb
Procedure type, n (%)
  LAR
  APR
  Definitive NOM
Proctectomy technique, n (%)
  Open
  Minimally invasive
  Missing
Months from diagnosis to TME, median (IQR)
Weeks from radiation completion to TME
  Median (IQR)
   <8, n (%)
   8–16, n (%)
   >16, n (%)
   Missing or no resection, n (%)
Margin status, n (%)
  Negative
  Positive
   Missing or no resection
Months from diagnosis to temporary stoma reversalc
  Median (IQR)

CRT (n = 226)

SC-TNT (n = 187)

p value

50.4 (45–50.4)

25 (25–25)

<0.01

220 (97.3)
6 (2.7)
1.1 (0.8–1.6)

0 (0.0)
187 (100.0)
1.1 (0.8–1.6)

<0.01
0.59

6.4 (5.8–7.2)

1.9 (1.6–2.5)

<0.01

0 (0–0)
143 (100.0)
0 (0)
0 (0)

6 (4–8)
0 (0)
54 (37.0)
92 (63.0)

<0.01
<0.01

186 (82.3)
39 (17.3)
1 (0.4)

107 (60.1)
59 (33.1)
12 (6.7)

<0.01

6 (0–8)
71 (49.6)
72 (50.4)

9 (7–12)
17 (11.6)
129 (88.4)

<0.01
<0.01

50 (22.1)
176 (77.9)

69 (36.7)
118 (63.1)

<0.01

137 (59.6)
89 (38.7)
0 (0.0)

130 (69.5)
48 (25.7)
9 (4.8)

<0.01

109 (48.3)
116 (51.3)
1 (0.4)
4.7 (4.1–5.2)

96 (53.9)
79 (44.4)
3 (1.7)
6.2 (5.1–7.7)

9 (7.9–10.6)
56 (24.8)
152 (67.3)
7 (3.1)
11 (4.8)

20 (16.5–25)
3 (1.6)
31 (17.4)
137 (77.0)
7 (4.0)

213 (94.3)
13 (5.8)
0 (0.0)

168 (94.4)
3 (1.7)
7 (3.9)

11.5 (10.2–13.6)

10.8 (10–12.3)

0.20

<0.01
<0.01
<0.01

<0.01

0.02

APR = abdominoperineal resection; CRT = chemoradiation therapy; Gy = Gray; IQR = interquartile range for variables described by median values; LAR = low anterior resection;
NOM = nonoperative management; SC-TNT = short-course radiation with total neoadjuvant therapy; TME = total mesorectal excision.
a
Analysis limited to patients for whom all chemotherapy details, including dates of treatment, were known.
b
Analysis excludes NOM recipients except where explicitly noted.
c
Only LAR recipients never nonoperatively managed included.

To date, no comparison of tumor downstaging
between TNT regimens utilizing short-course radiation
versus chemoradiation (CRT-TNT) has been performed.
Short-course 5 × 5 Gy has a biological effective dose of
approximately 37.5 Gy (for α/β ratio of 10), whereas 5
× 6 Gy may more closely approximate standard 50.4 Gy
in 28 fractions. Although comparisons across trials suggest that CRT-TNT may increase downstaging, studies

performing direct comparisons are needed to evaluate
optimal dosing.
The relationship between TNT regimens and survival, however, is more complex. In our series, SC-TNT
showed no significant association with recurrence rate or
progression-free survival despite earlier initiation of chemotherapy and higher therapy completion rates. The lack
of observed survival benefit in patients receiving SC-TNT
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in our data may be related to the uneven distribution of
follow-up time between cohorts. However, the same trend
was noted in other studies; the phase II Spanish GCR-3
trial also reported no difference in 5-year disease-free
survival between TNT recipients and those receiving
chemoradiation and adjuvant chemotherapy.24 Long-term
follow-up from the FOWARC trial also found no difference in 3-year disease-free survival and overall survival
between chemoradiation or TNT groups.25 Although the
Polish Colorectal Study Group reported initially increased
overall survival in the short-course arm (73% vs 65%;
p = 0.04),4 long-term follow-up in this cohort found no
survival difference at 7 years.26 Yet survival analysis from
the Timing of Rectal Cancer Response to Chemoradiation
Study Consortium found a positive association between
neoadjuvant consolidative chemotherapy and disease-free
survival that was not sensitive to dose of chemotherapy.27
Because treatment completion, in general, is much higher
among those receiving chemotherapy neoadjuvantly,1 the
conflicting conclusions regarding survival among TNT
recipients are surprising and require further study.
Treatment completion and tolerance also varied between
cohorts. Short-course total neoadjuvant therapy recipients
received 80% fewer radiation treatments and initiated multiagent chemotherapy 4.5 months sooner than patients receiving
chemoradiation. Eighty-eight percent of patients receiving
SC-TNT completed trimodal therapy, a surrogate marker of
treatment tolerance, compared with 50% of those treated with
chemoradiation and adjuvant therapy. Short-course total neoadjuvant therapy was associated with significantly less time with
diverting ostomies. Finally, the cumulative treatment course was
shorter in the SC-TNT cohort (10.8 vs 11.5 months); whether
this difference is attributable to shortened radiation duration or
other factors remains untested. Overall, SC-TNT was associated with fewer treatment visits, marginally shorter treatment
courses, and higher treatment completion compared with CRT.
In summary, SC-TNT achieves excellent oncologic
outcomes while meeting many goals of current oncologic
therapy. Surgery is performed after completion of all chemotherapy and even avoided in select cases. The cumulative radiation dose is reduced, and the time patients bear a
temporary stoma is significantly shortened. Most importantly, the oncologic outcomes are, at minimum, equivalent
with traditional therapy. These findings mirror recently
released randomized data from the OPRA28 and RAPIDO
trials,23 further supporting the utilization of delayed surgery and short-course TNT regimens in North America.
Short-course total neoadjuvant therapy is an ideal regimen
for rectal cancer treatment in the contemporary era.
Limitations

The results and conclusions of this study must be considered within the context of several limitations. First, the
2 cohorts differed significantly in location of treatment
because many patients undergoing CRT received their

initial neoadjuvant therapy from referring oncologists.
Although all patients underwent resection and surveillance
at our medical center, the difference in location of neoadjuvant treatment could not be controlled in this study
and may account for some of the observed differences in
outcomes between cohorts. Second, criteria for utilizing
CRT at Washington University before 2016 were not standardized; therefore, treatment selection may have biased
the results of this analysis. Cohort imbalance in tumor
height and nodal disease burden may represent such bias,
in particular, because SC-TNT was preferentially used in
patients with cN2 disease and higher tumors before institutional standardization. Third, cumulative follow-up time is
imbalanced between cohorts because a higher proportion
of patients received CRT early in the study period (before
SC-TNT was adopted). Therefore, CRT recipients have
accumulated more follow-up time and bear an increased
risk of recurrence (Supplementary Figure 1 http://links.
lww.com/DCR/B725). Finally, the retrospective nature of
this analysis precludes evaluation of any causative relationship between the neoadjuvant regimen and the outcomes
of interest or the independent effect of clinical variables
such as radiation course, time from radiation to surgery,
or amount of neoadjuvant chemotherapy. Also, the retrospective design precluded analysis of some variables
inconsistently collected across the study period‚ including
the total number of rectal cancers treated during the study
period, the percentage of cancers required emergent diversion in setting of obstruction, T-stage subclassification, and
MRI-detected extramural vascular invasion status. Longer
follow-up and prospective studies are needed to determine
whether such biases alter the material conclusions of this
analysis.

CONCLUSION
Compared with standard CRT, SC-TNT was associated
with higher rates of tumor downstaging, improved treatment completion, and fewer months with temporary stomas among patients with locally advanced rectal cancer.
There was no difference in recurrence or progression-free
survival between regimens despite earlier chemotherapy
administration and higher therapy completion rates in the
SC-TNT group.
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